Suppr超能文献

乳腺癌患者的DNA倍体与生存情况

DNA ploidy and survival in breast cancer patients.

作者信息

Cornelisse C J, van de Velde C J, Caspers R J, Moolenaar A J, Hermans J

出版信息

Cytometry. 1987 Mar;8(2):225-34. doi: 10.1002/cyto.990080217.

Abstract

Flow cytometric DNA ploidy measurements using frozen or deparaffinized tumor specimens were performed on 565 primary breast cancers from patients treated in the period 1975-1984. Twenty-nine percent of the cases were diploid, 61% had a single aneuploid stemline, and 10% were multiploid. Aneuploid tumors more often had negative estrogen receptor values than diploid tumors, but no significant correlation was found between ploidy class and TNM stage. Patients with more than ten positive axillary lymph nodes had predominantly aneuploid tumors. Overall and distant relapse-free survival were higher for patients with diploid tumors and low-aneuploid tumors. Stratification of the patients according to degree of lymph node involvement, TNM stage, and menopausal stage showed that the prognostic effect of aneuploidy was apparent predominantly in patients with locally advanced disease. Postmenopausal node-positive patients with diploid tumors had a significantly better prognosis than those with aneuploid tumors, but this difference was not found for the comparable premenopausal group. Multivariate analysis with the Cox proportional hazards model indicated that ploidy is an additional, independent prognostic factor in postmenopausal patients.

摘要

对1975年至1984年间接受治疗的565例原发性乳腺癌患者,使用冷冻或脱蜡肿瘤标本进行了流式细胞术DNA倍体测量。29%的病例为二倍体,61%有单一的非整倍体干系,10%为多倍体。非整倍体肿瘤的雌激素受体值比二倍体肿瘤更常为阴性,但倍体类别与TNM分期之间未发现显著相关性。腋窝淋巴结阳性超过十个的患者主要为非整倍体肿瘤。二倍体肿瘤和低非整倍体肿瘤患者的总体和远处无复发生存率更高。根据淋巴结受累程度、TNM分期和绝经阶段对患者进行分层显示,非整倍体的预后影响主要在局部晚期疾病患者中明显。绝经后二倍体肿瘤的淋巴结阳性患者的预后明显优于非整倍体肿瘤患者,但在可比的绝经前组中未发现这种差异。使用Cox比例风险模型进行多变量分析表明,倍体是绝经后患者的一个额外的独立预后因素。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验